Target
Cytochrome P450 2C19
Ligand
BDBM50041691
Substrate
n/a
Meas. Tech.
ChEMBL_1446306 (CHEMBL3373700)
IC50
>50000±n/a nM
Citation
 Buzard, DJKim, SHLopez, LKawasaki, AZhu, XMoody, JThoresen, LCalderon, IUllman, BHan, SLehmann, JGharbaoui, TSengupta, DCalvano, LMontalban, AGMa, YASage, CGao, YSemple, GEdwards, JBarden, JMorgan, MChen, WUsmani, KChen, CSadeque, AChristopher, RJThatte, JFu, LSolomon, MMills, DWhelan, KAl-Shamma, HGatlin, JLe, MGaidarov, IAnthony, TUnett, DJBlackburn, ARueter, JStirn, SBehan, DPJones, RM Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor. ACS Med Chem Lett 5:1313-7 (2014) [PubMed]  Article 
Target
Name:
Cytochrome P450 2C19
Synonyms:
(R)-limonene 6-monooxygenase | (S)-limonene 6-monooxygenase | (S)-limonene 7-monooxygenase | CP2CJ_HUMAN | CYP2C19 | CYPIIC17 | CYPIIC19 | Cytochrome P450 2C19 (CYP2C19) | Cytochrome P450 2C19 [I331V] | Cytochrome P450-11A | Cytochrome P450-254C | Fenbendazole monooxygenase (4'-hydroxylating) | Mephenytoin 4-hydroxylase | P450-11A | P450-254C
Type:
Enzyme
Mol. Mass.:
55935.47
Organism:
Homo sapiens (Human)
Description:
P33261
Residue:
490
Sequence:
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKIYGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRWKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICSIIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFMESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRGHMPYTDAVVHEVQRYIDLIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFKKSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVPPFYQLCFIPV
  
Inhibitor
Name:
BDBM50041691
Synonyms:
CHEMBL3358920 | US11149292, Compound (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-
Type:
Small organic molecule
Emp. Form.:
C26H26F3NO3
Mol. Mass.:
457.4847
SMILES:
OC(=O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(c3)C(F)(F)F)cc21 |r|
Structure:
Search PDB for entries with ligand similarity: